Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR) shares experienced significant volatility on Monday, surging 111.84% intraday to $8.41 before falling 22.47% in after-hours trading to $6.52. The sharp price movement followed the company's disclosure in a Form 6-K filing that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for MEDIFLY Maggots. This clearance represents the first U.S. regulatory approval for a maggot debridement product utilizing the Lucilia cuprina species, granting the company U.S. commercial rights to both primary maggot species used in maggot debridement therapy (MDT).

Regulatory and Commercial Position

The FDA clearance was granted by the Center for Biologics Evaluation and Research (CBER). MEDIFLY Maggots was deemed substantially equivalent to Medical Maggots, a Lucilia sericata product first cleared in 2004. Cuprina is the licensed producer and distributor of Medical Maggots for the U.S. market. Chief Executive Officer David Quek stated that the dual-species FDA clearance gives Cuprina a competitive edge as it expands its wound-care portfolio.

Product Application and Market Context

MEDIFLY Maggots consists of medical-grade fly larvae applied to wounds under the supervision of trained healthcare professionals. The prescription product is indicated for the debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and traumatic or post-surgical wounds. The therapy removes dead and infected tissue to support the body's natural healing process. As a biological, non-antibiotic approach, MDT is gaining attention amid global concerns over antimicrobial resistance.

Trading Metrics

Cuprina has a market capitalization of $22.55 million, a 52-week high of $76.00, and a 52-week low of $1.76. The stock is currently trading at about 8.9% of its 52-week range. Benzinga's Edge Stock Rankings indicate that Cuprina has a positive price trend over the short and medium term, while the long-term trend remains negative.

Cuprina Holdings (Cayman) Limited stock traded little changed on Monday as investors digested last week's compliance-driven rally that sent the biomedical company's shares sharply higher. The stock was down 1.76% at $3.90 during premarket trading, following a breakout session on Friday where CUPR soared 64.73% to close at $3.97. With a small public float, Cuprina can experience outsized price swings, as modest changes in retail trading volume often trigger sharp rallies or steep pullbacks.

The surge came after Cuprina announced it had regained compliance with Nasdaq Capital Market listing requirements, removing the risk of delisting. Nasdaq's Listing Qualifications staff informed the exchange's Hearings Department that Cuprina satisfies the minimum bid price requirement and is fully compliant with Nasdaq Capital Market rules. Consequently, a hearing before the Nasdaq Hearing Panel scheduled for July 7, 2026, has been cancelled.

Cuprina had received a Staff Delisting Determinations Letter on May 29, 2026, after its securities closed below $1.00 for 30 consecutive business days. The company failed to regain compliance within the initial 180-day grace period under Listing Rule 5810(c)(3)(a). In response, Cuprina appealed the determination and requested a hearing under Listing Rule 5815 to stay any suspension pending the appeal.

Compliance Timeline

"We are gratified to regain compliance with Nasdaq," said CEO David Quek. He added that the company looks forward to continuing its initiatives to grow Cuprina's business in multiple biomedical sectors. Cuprina develops and markets products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.